Facial Rejuvenation
Conditions
Interventions
fractional radiofrequency microneedling group:Implementation of fractional radiofrequency microneedling therapy
interventional radiofrequency mononeedling group:Implementation of interventional radiofrequency mononeedling therapy
Sponsors
Chengdu Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients dissatisfied with their facial appearance or voluntarily requesting treatment; 2. Subjects with mild to moderate facial and neck laxity ratings; 3. Age range: 18 to 60 years old; 4. Subjects with good compliance who fully understand this clinical trial, have reasonable expectations regarding the cosmetic effects of high-frequency technology treatment, and can adhere to the study protocol until the trial concludes; 5. Subjects who voluntarily sign the informed consent form after fully understanding the trial requirements; 6. Patients who have not undergone other facial anti-aging treatments within the past 6 months and will not receive other facial anti-aging treatments during the study period; 7. No significant asymmetry between the left and right sides of the face.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or lactation; 2. Skin lesions or severe acne in the treatment area; 3. Allergy to topical anesthetics; 4. Individuals with keloid-prone skin, autoimmune diseases, severe cardiovascular/cerebrovascular conditions, or malignant tumors; 5. Presence of metallic foreign bodies or fillers in the treatment area that may interfere with the procedure; 6. Participants who have enrolled in any other clinical trial within 3 months prior to screening, or who have undergone facial rejuvenation treatments within 6 months prior to screening or plan to do so during the study period; individuals with poor compliance, inability to complete the full treatment course, unwillingness to attend follow-up visits, or concurrent participation in other clinical trials; 7. Use of topical skin medications (e.g., corticosteroids, tretinoin ointment) within 4 weeks prior to screening, or use of medications prolonging coagulation time within 2 weeks prior to screening that may affect experimental observations; 8. Subjects with central nervous system disorders or psychiatric conditions that prevent adequate understanding and cooperation; 9. Subjects with high treatment expectations, other comorbidities deemed by the investigator to potentially interfere with study assessments, or situations where the investigator believes participation may expose the subject to increased risk; 10. Other circumstances deemed by the investigator to make participation in this study inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VISIA Score;Thickness of the dermis and epidermis;Facial volume changes; | — |
Countries
China
Contacts
Public ContactWa Qingbiao
Chengdu Second People's Hospital
Outcome results
None listed